Medeon Biodesign Stock Probability Of Bankruptcy
| 6499 Stock | TWD 39.15 0.05 0.13% |
Medeon |
Medeon Biodesign Company odds of financial turmoil Analysis
Medeon Biodesign's Probability Of Bankruptcy is a relative measure of the likelihood of financial distress. For stocks, the Probability Of Bankruptcy is the normalized value of Z-Score. For funds and ETFs, it is derived from a multi-factor model developed by Macroaxis. The score is used to predict the probability of a firm or a fund experiencing financial distress within the next 24 months. Unlike Z-Score, Probability Of Bankruptcy is the value between 0 and 100, indicating the firm's actual probability it will be financially distressed in the next 2 fiscal years.
More About Probability Of Bankruptcy | All Equity Analysis
Probability Of Bankruptcy | = | Normalized | | Z-Score |
Current Medeon Biodesign Probability Of Bankruptcy | Over 65% |
Most of Medeon Biodesign's fundamental indicators, such as Probability Of Bankruptcy, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Medeon Biodesign is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Our calculation of Medeon Biodesign probability of bankruptcy is based on Altman Z-Score and Piotroski F-Score, but not limited to these measures. To be applied to a broader range of industries and markets, we use several other techniques to enhance the accuracy of predicting Medeon Biodesign odds of financial distress. These include financial statement analysis, different types of price predictions, earning estimates, analysis consensus, and basic intrinsic valuation. Please use the options below to get a better understanding of different measures that drive the calculation of Medeon Biodesign financial health.
The Probability of Bankruptcy SHOULD NOT be confused with the actual chance of a company to file for chapter 7, 11, 12, or 13 bankruptcy protection. Macroaxis simply defines Financial Distress as an operational condition where a company is having difficulty meeting its current financial obligations towards its creditors or delivering on the expectations of its investors. Macroaxis derives these conditions daily from both public financial statements as well as analysis of stock prices reacting to market conditions or economic downturns, including short-term and long-term historical volatility. Other factors taken into account include analysis of liquidity, revenue patterns, R&D expenses, and commitments, as well as public headlines and social sentiment.
| Competition |
Based on the latest financial disclosure, Medeon Biodesign has a Probability Of Bankruptcy of 65%. This is 50.15% higher than that of the Healthcare sector and 79.31% higher than that of the Medical Instruments & Supplies industry. The probability of bankruptcy for all Taiwan stocks is 63.19% lower than that of the firm.
Medeon Probability Of Bankruptcy Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Medeon Biodesign's direct or indirect competition against its Probability Of Bankruptcy to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Medeon Biodesign could also be used in its relative valuation, which is a method of valuing Medeon Biodesign by comparing valuation metrics of similar companies.Medeon Biodesign is currently under evaluation in probability of bankruptcy category among its peers.
Medeon Fundamentals
| Return On Equity | -0.1 | |||
| Return On Asset | -0.0639 | |||
| Profit Margin | (1.31) % | |||
| Operating Margin | (1.64) % | |||
| Current Valuation | 3.37 B | |||
| Shares Outstanding | 87.64 M | |||
| Shares Owned By Insiders | 50.07 % | |||
| Shares Owned By Institutions | 4.65 % | |||
| Price To Book | 1.29 X | |||
| Price To Sales | 19.67 X | |||
| Revenue | 68.96 M | |||
| Gross Profit | 28.63 M | |||
| EBITDA | (453.87 M) | |||
| Net Income | 2.08 B | |||
| Book Value Per Share | 43.26 X | |||
| Cash Flow From Operations | (293.38 M) | |||
| Earnings Per Share | 30.41 X | |||
| Number Of Employees | 16 | |||
| Beta | 0.79 | |||
| Market Capitalization | 5 B | |||
| Total Asset | 4.36 B | |||
| Annual Yield | 0.02 % | |||
| Net Asset | 4.36 B | |||
| Last Dividend Paid | 0.83 |
About Medeon Biodesign Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Medeon Biodesign's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Medeon Biodesign using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Medeon Biodesign based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Pair Trading with Medeon Biodesign
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Medeon Biodesign position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Medeon Biodesign will appreciate offsetting losses from the drop in the long position's value.Moving together with Medeon Stock
Moving against Medeon Stock
| 0.87 | 4111 | Chi Sheng Chemical | PairCorr |
| 0.82 | 2881A | Fubon Financial Holding | PairCorr |
| 0.77 | 2882B | Cathay Financial Holding | PairCorr |
| 0.74 | 5312 | Formosa Optical Tech | PairCorr |
| 0.63 | 2881B | Fubon Financial Holding | PairCorr |
The ability to find closely correlated positions to Medeon Biodesign could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Medeon Biodesign when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Medeon Biodesign - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Medeon Biodesign to buy it.
The correlation of Medeon Biodesign is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Medeon Biodesign moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Medeon Biodesign moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Medeon Biodesign can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Medeon Stock Analysis
When running Medeon Biodesign's price analysis, check to measure Medeon Biodesign's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Medeon Biodesign is operating at the current time. Most of Medeon Biodesign's value examination focuses on studying past and present price action to predict the probability of Medeon Biodesign's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Medeon Biodesign's price. Additionally, you may evaluate how the addition of Medeon Biodesign to your portfolios can decrease your overall portfolio volatility.